Pub Date : 2022-01-13DOI: 10.18203/2319-2003.ijbcp20220024
J. Zepeda, Alejandro Murrieta, J. Contreras, Felix Osuna, Luis Antonio Villalobos Calderon, Miriam Pérez, María Holanda García Ramírez, Omar De J. Dorantes
It is estimated that currently, in the world, approximately 3% of the population has chronic hepatitis, the hepatitis C virus is the etiological agent most related to the development of this pathology. The diversity of genotypes (7) and quasi-species of HCV, due to its high mutation rate, interferes with an effective humoral immunity. The aim of this work is precisely to evoke those usual drugs used in HCV therapy, as well as cutting-edge drugs. The goal of treatment is the eradication of HCV infection. One strategy offered by the WHO is to eradicate the virus in at-risk populations. Alternatives to the previously used treatment with interferon and ribavirin are shown in this paper; protease inhibitors and other targets have now been developed to make eradication of the virus more effective.
{"title":"Efficacy of current treatments against hepatitis C virus","authors":"J. Zepeda, Alejandro Murrieta, J. Contreras, Felix Osuna, Luis Antonio Villalobos Calderon, Miriam Pérez, María Holanda García Ramírez, Omar De J. Dorantes","doi":"10.18203/2319-2003.ijbcp20220024","DOIUrl":"https://doi.org/10.18203/2319-2003.ijbcp20220024","url":null,"abstract":"It is estimated that currently, in the world, approximately 3% of the population has chronic hepatitis, the hepatitis C virus is the etiological agent most related to the development of this pathology. The diversity of genotypes (7) and quasi-species of HCV, due to its high mutation rate, interferes with an effective humoral immunity. The aim of this work is precisely to evoke those usual drugs used in HCV therapy, as well as cutting-edge drugs. The goal of treatment is the eradication of HCV infection. One strategy offered by the WHO is to eradicate the virus in at-risk populations. Alternatives to the previously used treatment with interferon and ribavirin are shown in this paper; protease inhibitors and other targets have now been developed to make eradication of the virus more effective.","PeriodicalId":13901,"journal":{"name":"International Journal of Basic & Clinical Pharmacology","volume":"53 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90407048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-13DOI: 10.18203/2319-2003.ijbcp20220043
Marya Ahsan, A. Mallick
A significant proportion of patients exhibit sub-optimal response to the standard treatment of acute migraine such as triptans and NSAIDs. Even the conventional preventive therapies (e.g. beta-blockers) indicated for patients with frequent migraine attacks have varying responses. Moreover, evidence from animal studies elucidated the role of calcitonin gene-related peptide (CGRP) in the pathophysiology of migraine. Currently two classes are drug, the small molecule CGRP receptor antagonist or the ‘gepants’ (Ubrogepant, Rimegepant, Atogepant, Zavegepant) and CGRP monoclonal antibodies (Erenumab, Galcanezumab, Fremanezumab, Eptinezumab) have been found efficacious and safe in various clinical trials for the treatment and prevention of migraine. While the small molecule CGRP receptor antagonists are given orally, the monoclonal antibodies are injectable drugs. Ubrogepant and Rimegepant are the second-generation gepants approved for treatment of migraine. Zavegepant is a third generation gepant which has proven efficacy for acute treatment of migraine in a phase III trial. Atogepant has been approved for prevention of migraine. Rimegepant has also proven to be efficacious for preventing migraine attacks but has not yet been approved for this indication. Erenumab is the only monoclonal antibody which neutralizes the CGRP receptor. The latter three monoclonal antibodies target the CGRP peptide. The monoclonal antibodies have been approved for the prevention of migraine as a subcutaneously or intravenous infusion (Eptinezumab) given once a month or quarterly. Both the classes of drugs were well-tolerated in the clinical trials. Nausea was the most common adverse effect with gepants while injection-site pain was commonly reported with the antibodies.
{"title":"Current status of calcitonin gene-related peptide-based therapies in migraine: a scoping review","authors":"Marya Ahsan, A. Mallick","doi":"10.18203/2319-2003.ijbcp20220043","DOIUrl":"https://doi.org/10.18203/2319-2003.ijbcp20220043","url":null,"abstract":"A significant proportion of patients exhibit sub-optimal response to the standard treatment of acute migraine such as triptans and NSAIDs. Even the conventional preventive therapies (e.g. beta-blockers) indicated for patients with frequent migraine attacks have varying responses. Moreover, evidence from animal studies elucidated the role of calcitonin gene-related peptide (CGRP) in the pathophysiology of migraine. Currently two classes are drug, the small molecule CGRP receptor antagonist or the ‘gepants’ (Ubrogepant, Rimegepant, Atogepant, Zavegepant) and CGRP monoclonal antibodies (Erenumab, Galcanezumab, Fremanezumab, Eptinezumab) have been found efficacious and safe in various clinical trials for the treatment and prevention of migraine. While the small molecule CGRP receptor antagonists are given orally, the monoclonal antibodies are injectable drugs. Ubrogepant and Rimegepant are the second-generation gepants approved for treatment of migraine. Zavegepant is a third generation gepant which has proven efficacy for acute treatment of migraine in a phase III trial. Atogepant has been approved for prevention of migraine. Rimegepant has also proven to be efficacious for preventing migraine attacks but has not yet been approved for this indication. Erenumab is the only monoclonal antibody which neutralizes the CGRP receptor. The latter three monoclonal antibodies target the CGRP peptide. The monoclonal antibodies have been approved for the prevention of migraine as a subcutaneously or intravenous infusion (Eptinezumab) given once a month or quarterly. Both the classes of drugs were well-tolerated in the clinical trials. Nausea was the most common adverse effect with gepants while injection-site pain was commonly reported with the antibodies.","PeriodicalId":13901,"journal":{"name":"International Journal of Basic & Clinical Pharmacology","volume":"32 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87393653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tuberculosis (TB) continues to be an important public health problem throughout much of the world. Drug treatment is the only effective treatment method, but adverse drug events (ADEs) and adverse drug reactions (ADRs) can affect medical adherence. As the number of drug resistant TB patients and the number of anti-TB drugs have increased, it is necessary to explore the risk factors for ADEs/ADRs to reduce their occurrence. Here we reported three different cases of ADRs due to first line anti-tubercular drugs.
{"title":"Adverse drug reactions to first line anti-tuberculosis drugs in newly diagnosed tuberculosis patients","authors":"Elakkya Kolanchinathan, D. Harichandran, Sujatha Mangattuvalappil Balakrishnan, Sanal Kumar Kondarappassery Balakumaran","doi":"10.18203/2319-2003.ijbcp20214891","DOIUrl":"https://doi.org/10.18203/2319-2003.ijbcp20214891","url":null,"abstract":"Tuberculosis (TB) continues to be an important public health problem throughout much of the world. Drug treatment is the only effective treatment method, but adverse drug events (ADEs) and adverse drug reactions (ADRs) can affect medical adherence. As the number of drug resistant TB patients and the number of anti-TB drugs have increased, it is necessary to explore the risk factors for ADEs/ADRs to reduce their occurrence. Here we reported three different cases of ADRs due to first line anti-tubercular drugs.","PeriodicalId":13901,"journal":{"name":"International Journal of Basic & Clinical Pharmacology","volume":"46 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75054258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-23DOI: 10.18203/2319-2003.ijbcp20214884
G. Agrawal, Ruchira Agrawal, Harsh Agrawal, Hiren K. Prajapati, K. Yadav, K. Agrawal, C. Agrawal
Background: The study was conducted to determine the Coronavirus disease 2019 (COVID-19) antibody titre among patients who visited our clinic in Lucknow in order to find out the prevalence of sero positivity and to determine the association between COVID anti-body titre and positivity to different age groups, sex, and religions etc., if any.Methods: Secondary data analysis was conducted at Lucknow's Sitara polyclinic from patients’ data, who had attended the clinic between May 2021 and July 2021 and had universally undergone COVID antibody testing. COVID antibody (including IgG) levels in patients' blood were determined using Roche's commercial "Elecsys Anti-SARS-CoV2-cobas e411,601,602 system.by Roche which measure by Eclia (electro chemilusence immunoassay) quantitatively antibodies (including IgG). Patients with titres less than 1 u/ml were deemed seronegative for anti –SARS COVID-2, while those with titres greater than or equal to 1 u/ml were declared seropositive.Results: The overall rate of seropositivity was 84.8%. Around 84.5% males and 85.1% females were seropositive. Seropositivity was higher among 18 to 60 years of age. But there was no significant relation between mean age and seropositivity. Muslims had slightly higher seropositivity (86.0%) as compared to non-Muslims (84.5%). There was no significant difference between age and gender having positive COVID 19 antibody titres. Although the incidence of seropositivity was similar between Muslims and Non-Muslims, the antibody titres were significantly higher in Muslim patients.Conclusions: In this part of central eastern UP, incidence of seropositivity could already be as high as 85%, which is a pointer toward adequate herd immunity. COVID-19 does not differentiate on the basis of age, gender or religious affiliations. However, Muslims were found to have more antibody titres compared to non-Muslims, possibly related to life style, degree of exposure to COVID-19 virus and presence of inherent immunity.
{"title":"Seroprevalence of COVID-19 antibody among patients visiting a large clinic in Uttar Pradesh","authors":"G. Agrawal, Ruchira Agrawal, Harsh Agrawal, Hiren K. Prajapati, K. Yadav, K. Agrawal, C. Agrawal","doi":"10.18203/2319-2003.ijbcp20214884","DOIUrl":"https://doi.org/10.18203/2319-2003.ijbcp20214884","url":null,"abstract":"Background: The study was conducted to determine the Coronavirus disease 2019 (COVID-19) antibody titre among patients who visited our clinic in Lucknow in order to find out the prevalence of sero positivity and to determine the association between COVID anti-body titre and positivity to different age groups, sex, and religions etc., if any.Methods: Secondary data analysis was conducted at Lucknow's Sitara polyclinic from patients’ data, who had attended the clinic between May 2021 and July 2021 and had universally undergone COVID antibody testing. COVID antibody (including IgG) levels in patients' blood were determined using Roche's commercial \"Elecsys Anti-SARS-CoV2-cobas e411,601,602 system.by Roche which measure by Eclia (electro chemilusence immunoassay) quantitatively antibodies (including IgG). Patients with titres less than 1 u/ml were deemed seronegative for anti –SARS COVID-2, while those with titres greater than or equal to 1 u/ml were declared seropositive.Results: The overall rate of seropositivity was 84.8%. Around 84.5% males and 85.1% females were seropositive. Seropositivity was higher among 18 to 60 years of age. But there was no significant relation between mean age and seropositivity. Muslims had slightly higher seropositivity (86.0%) as compared to non-Muslims (84.5%). There was no significant difference between age and gender having positive COVID 19 antibody titres. Although the incidence of seropositivity was similar between Muslims and Non-Muslims, the antibody titres were significantly higher in Muslim patients.Conclusions: In this part of central eastern UP, incidence of seropositivity could already be as high as 85%, which is a pointer toward adequate herd immunity. COVID-19 does not differentiate on the basis of age, gender or religious affiliations. However, Muslims were found to have more antibody titres compared to non-Muslims, possibly related to life style, degree of exposure to COVID-19 virus and presence of inherent immunity.","PeriodicalId":13901,"journal":{"name":"International Journal of Basic & Clinical Pharmacology","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88997525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-23DOI: 10.18203/2319-2003.ijbcp20214886
A. Dhavaleshwar, Bharti Chogtu, Deepak Nayak, Praveen Kumar S. E.
Background: The clinical studies have shown contrary results regarding hepatoprotective effect of statins. However, antifibrotic properties of statins in in vitro and in vivo experimental models have been demonstrated. The purpose of this study was to assess and compare the effect of statins on serum liver enzymes and their antifibrotic effects.Methods: Forty two rats were divided into 7 groups (I to VII) (n=6). Liver toxicity was induced by injecting carbon tetrachloride (1 ml/kg). Control groups received corn oil (0.1 ml/100 gm) and carboxy methyl cellulose (0.50%) respectively. Group III to VII received carbon tetrachloride (CCl4) for 6 weeks and then groups IV, V, VI and VII received simvastatin (10 mg/kg), atorvastatin (15 mg/kg), rosuvastatin (2 mg/kg) and silymarin (50 mg/kg) for another 8 weeks respectively. Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) levels were estimated in all the groups at baseline, 6 weeks and 14 weeks. At 14 weeks, histopathology of liver was done in all groups.Results: At 14 weeks, all the test groups (IV, V and VI) showed a significant decrease in serum ALT, AST and ALP levels as compared to control (p<0.05) and group III (p<0.05). On intergroup comparison, liver enzymes in rats in group VI (rosuvastatin) and group V (atorvastatin) were decreased more in comparison to group IV (simvastatin) but the difference was not statistically significant except for AST levels where the difference was significant between the statins. There was decrease in hepatic fibrosis by statins with rosuvastatin being superior followed by atorvastatin and simvastatin.Conclusions: In the present study statins decreased the serum AST, ALT and ALP levels and histopathological changes were reversed by statins in CCl4 induced hepatotoxic models.
{"title":"Comparing the effect of statins on hepatic fibrosis induced by carbon tetrachloride in Wistar rats","authors":"A. Dhavaleshwar, Bharti Chogtu, Deepak Nayak, Praveen Kumar S. E.","doi":"10.18203/2319-2003.ijbcp20214886","DOIUrl":"https://doi.org/10.18203/2319-2003.ijbcp20214886","url":null,"abstract":"Background: The clinical studies have shown contrary results regarding hepatoprotective effect of statins. However, antifibrotic properties of statins in in vitro and in vivo experimental models have been demonstrated. The purpose of this study was to assess and compare the effect of statins on serum liver enzymes and their antifibrotic effects.Methods: Forty two rats were divided into 7 groups (I to VII) (n=6). Liver toxicity was induced by injecting carbon tetrachloride (1 ml/kg). Control groups received corn oil (0.1 ml/100 gm) and carboxy methyl cellulose (0.50%) respectively. Group III to VII received carbon tetrachloride (CCl4) for 6 weeks and then groups IV, V, VI and VII received simvastatin (10 mg/kg), atorvastatin (15 mg/kg), rosuvastatin (2 mg/kg) and silymarin (50 mg/kg) for another 8 weeks respectively. Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) levels were estimated in all the groups at baseline, 6 weeks and 14 weeks. At 14 weeks, histopathology of liver was done in all groups.Results: At 14 weeks, all the test groups (IV, V and VI) showed a significant decrease in serum ALT, AST and ALP levels as compared to control (p<0.05) and group III (p<0.05). On intergroup comparison, liver enzymes in rats in group VI (rosuvastatin) and group V (atorvastatin) were decreased more in comparison to group IV (simvastatin) but the difference was not statistically significant except for AST levels where the difference was significant between the statins. There was decrease in hepatic fibrosis by statins with rosuvastatin being superior followed by atorvastatin and simvastatin.Conclusions: In the present study statins decreased the serum AST, ALT and ALP levels and histopathological changes were reversed by statins in CCl4 induced hepatotoxic models.","PeriodicalId":13901,"journal":{"name":"International Journal of Basic & Clinical Pharmacology","volume":"121 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75846220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-23DOI: 10.18203/2319-2003.ijbcp20214885
O. Sari, G. Z. Saputri, A. -
Background: For chronic disease patients, pharmacist counselling with motivating reminder messages has been developed throughout time to promote the success of patient treatment. Diabetes mellitus is a long-term condition. Blood sugar control and an improved quality of life are therapeutic goals in the treatment of diabetes mellitus. The objective of this study was to determine whether changes in fasting blood sugar and quality of life occurred in individuals with diabetes mellitus who received pharmacist counselling coupled by motivating reminder messages.Methods: This quasi-experimental study used a pre-test-post-test design with control and intervention groups. Data on patients with type 2 diabetes were obtained prospectively at Jetis 1 primary health care in Bantul, Yogyakarta, Indonesia. Seventy-two respondents who met the inclusion criteria were separated into two groups: the control group (36 participants) and the intervention group (36 participants). The patients’ quality of life was assessed using the 36-item Short Form (SF-36) questionnaire.Results: Following pharmacist counselling coupled by motivating reminder messages, patients’ mean fasting blood sugar reduced significantly (∆ 34.85±63.36), while their mean quality of life score increased considerably (∆ 13.73±9.22).Conclusions: Pharmacist counselling combined with motivating reminder messages can help patients with type 2 diabetes lower their fasting blood sugar and enhance their quality of life. The provision of pharmacist counselling followed by brief reminders and motivational messages may be considered to improve type 2 diabetes patient management.
{"title":"Diabetes mellitus patients’ fasting blood sugar levels and quality of life following brief pharmacist counseling with reminders and motivational messages","authors":"O. Sari, G. Z. Saputri, A. -","doi":"10.18203/2319-2003.ijbcp20214885","DOIUrl":"https://doi.org/10.18203/2319-2003.ijbcp20214885","url":null,"abstract":"Background: For chronic disease patients, pharmacist counselling with motivating reminder messages has been developed throughout time to promote the success of patient treatment. Diabetes mellitus is a long-term condition. Blood sugar control and an improved quality of life are therapeutic goals in the treatment of diabetes mellitus. The objective of this study was to determine whether changes in fasting blood sugar and quality of life occurred in individuals with diabetes mellitus who received pharmacist counselling coupled by motivating reminder messages.Methods: This quasi-experimental study used a pre-test-post-test design with control and intervention groups. Data on patients with type 2 diabetes were obtained prospectively at Jetis 1 primary health care in Bantul, Yogyakarta, Indonesia. Seventy-two respondents who met the inclusion criteria were separated into two groups: the control group (36 participants) and the intervention group (36 participants). The patients’ quality of life was assessed using the 36-item Short Form (SF-36) questionnaire.Results: Following pharmacist counselling coupled by motivating reminder messages, patients’ mean fasting blood sugar reduced significantly (∆ 34.85±63.36), while their mean quality of life score increased considerably (∆ 13.73±9.22).Conclusions: Pharmacist counselling combined with motivating reminder messages can help patients with type 2 diabetes lower their fasting blood sugar and enhance their quality of life. The provision of pharmacist counselling followed by brief reminders and motivational messages may be considered to improve type 2 diabetes patient management.","PeriodicalId":13901,"journal":{"name":"International Journal of Basic & Clinical Pharmacology","volume":"82 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80527374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-23DOI: 10.18203/2319-2003.ijbcp20214890
Shashikala Eda, Somnath Motgi, Rohit Singh, Vijay Raghawa Rao B. N.
Background: Diabetes mellitus (DM) is the most common non-communicable diseases in the present millennium which has become a global public health problem. The treatment of type 2 Diabetes mellitus (T2 DM) often is initiated with monotherapy of oral antidiabetic drugs (OADs), which often do not decrease the plasma sugar levels effectively and consistently that will reduce short term and long-term complications associated with T2 DM. Hence the current study is aimed to determine the effectiveness of vitamin C supplementation with standard OADs on glycemic control.Methods: This study consisted of 120 T2 DM patients with 80 males and 40 females with a mean age of 50.88 yrs were divided into four groups with equal number of males and females in each group depending upon the OADs they received in solo or with vitamin C for 12 weeks. After the written consent, a detail clinical history, clinical examination, biochemical investigations including fasting plasma sugar (FPS), post prandial plasma sugar (PPS), glycosylated hemoglobin (HBA1c), serum creatinine, serum electrolytes, chest X-ray PA view and standard ECG were done. Repeat FPS, PPS and HBA1c were done after 4, 8 and 12 weeks of study.Results: After 12 weeks of study FBS, PPS and HBA1c decreased significantly (p<0.01) in study groups (Metformin and teneligliptin with vitamin C) as compared to control groups (OADs without vitamin C). Vitamin C supplementation with OADs found to be effective, well tolerated and devoid of any side effects.Conclusions: OADs are effective and affordable hypoglycemic agents with vitamin C supplementation.
{"title":"Study of role of vitamin C in type 2 diabetes mellitus patients","authors":"Shashikala Eda, Somnath Motgi, Rohit Singh, Vijay Raghawa Rao B. N.","doi":"10.18203/2319-2003.ijbcp20214890","DOIUrl":"https://doi.org/10.18203/2319-2003.ijbcp20214890","url":null,"abstract":"Background: Diabetes mellitus (DM) is the most common non-communicable diseases in the present millennium which has become a global public health problem. The treatment of type 2 Diabetes mellitus (T2 DM) often is initiated with monotherapy of oral antidiabetic drugs (OADs), which often do not decrease the plasma sugar levels effectively and consistently that will reduce short term and long-term complications associated with T2 DM. Hence the current study is aimed to determine the effectiveness of vitamin C supplementation with standard OADs on glycemic control.Methods: This study consisted of 120 T2 DM patients with 80 males and 40 females with a mean age of 50.88 yrs were divided into four groups with equal number of males and females in each group depending upon the OADs they received in solo or with vitamin C for 12 weeks. After the written consent, a detail clinical history, clinical examination, biochemical investigations including fasting plasma sugar (FPS), post prandial plasma sugar (PPS), glycosylated hemoglobin (HBA1c), serum creatinine, serum electrolytes, chest X-ray PA view and standard ECG were done. Repeat FPS, PPS and HBA1c were done after 4, 8 and 12 weeks of study.Results: After 12 weeks of study FBS, PPS and HBA1c decreased significantly (p<0.01) in study groups (Metformin and teneligliptin with vitamin C) as compared to control groups (OADs without vitamin C). Vitamin C supplementation with OADs found to be effective, well tolerated and devoid of any side effects.Conclusions: OADs are effective and affordable hypoglycemic agents with vitamin C supplementation.","PeriodicalId":13901,"journal":{"name":"International Journal of Basic & Clinical Pharmacology","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81111116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-23DOI: 10.18203/2319-2003.ijbcp20214892
Murshid C. P., B. Shareef, P. Hema
Neuroleptic malignant syndrome (NMS) is an infrequent, but potentially life-threatening neurologic emergency associated with the use of neuroleptic or antipsychotic drugs. A 43 years old male with a history of trigeminal neuralgia developed Neuroleptic malignant syndrome while receiving Carbamazepine and Amitryptylline. Treatment is mainly supportive and includes withdrawal of the neuroleptic medication and, possibly, administration of drugs such as dantrolene and bromocriptine. Complications of NMS include acute renal failure and acute respiratory failure. The possible etiologies, triggering factors and treatment are discussed with reference to existing literature.
{"title":"Neuroleptic malignant syndrome: case report","authors":"Murshid C. P., B. Shareef, P. Hema","doi":"10.18203/2319-2003.ijbcp20214892","DOIUrl":"https://doi.org/10.18203/2319-2003.ijbcp20214892","url":null,"abstract":"Neuroleptic malignant syndrome (NMS) is an infrequent, but potentially life-threatening neurologic emergency associated with the use of neuroleptic or antipsychotic drugs. A 43 years old male with a history of trigeminal neuralgia developed Neuroleptic malignant syndrome while receiving Carbamazepine and Amitryptylline. Treatment is mainly supportive and includes withdrawal of the neuroleptic medication and, possibly, administration of drugs such as dantrolene and bromocriptine. Complications of NMS include acute renal failure and acute respiratory failure. The possible etiologies, triggering factors and treatment are discussed with reference to existing literature.","PeriodicalId":13901,"journal":{"name":"International Journal of Basic & Clinical Pharmacology","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80151859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-23DOI: 10.18203/2319-2003.ijbcp20214889
Rohan Srivastava, N. Kantharia
Background: The data regarding effects of amitriptyline and pregabalin on heart rate variability in patients with neuropathic pain in diabetic patients are poorly understood in India. The present study was conducted to evaluate the effect of amitriptyline and pregabalin on heart rate variability in diabetic patients with neuropathic pain and their effect on serum electrolyte (sodium and potassium).Methods: The patients include 60 diabetic patients of either sex aged 18-65 years diagnosed with neuropathic pain and divided into two groups. The study was prospective open label and observational study. Group 1 was treated with amitriptyline 10 mg once a day while group 2 with pregabalin 75 mg once a day and HRV, serum sodium and serum potassium levels and pain score were recorded; and data of post-treatment at 2 and 4 weeks were compared with pretreatment values (control). All the statistical analysis was performed by using SPSS 20.0 software.Results: Both the drugs have increased HRV and reduced neuropathic pain intensity after 2 and 4 weeks treatment. The sodium and potassium level were not altered by these drugs. No correlation was observed between HRV and neuropathic pain.Conclusions: In conclusion, both the amitriptyline and pregabalin have significantly increased HRV and reduced the neuropathic pain intensity; but no correlation was observed between increased HRV and reduced neuropathic pain intensity.
{"title":"Effect of amitriptyline and pregabalin on heart rate variability and electrolytes in neurotrophic pain in diabetic patients","authors":"Rohan Srivastava, N. Kantharia","doi":"10.18203/2319-2003.ijbcp20214889","DOIUrl":"https://doi.org/10.18203/2319-2003.ijbcp20214889","url":null,"abstract":"Background: The data regarding effects of amitriptyline and pregabalin on heart rate variability in patients with neuropathic pain in diabetic patients are poorly understood in India. The present study was conducted to evaluate the effect of amitriptyline and pregabalin on heart rate variability in diabetic patients with neuropathic pain and their effect on serum electrolyte (sodium and potassium).Methods: The patients include 60 diabetic patients of either sex aged 18-65 years diagnosed with neuropathic pain and divided into two groups. The study was prospective open label and observational study. Group 1 was treated with amitriptyline 10 mg once a day while group 2 with pregabalin 75 mg once a day and HRV, serum sodium and serum potassium levels and pain score were recorded; and data of post-treatment at 2 and 4 weeks were compared with pretreatment values (control). All the statistical analysis was performed by using SPSS 20.0 software.Results: Both the drugs have increased HRV and reduced neuropathic pain intensity after 2 and 4 weeks treatment. The sodium and potassium level were not altered by these drugs. No correlation was observed between HRV and neuropathic pain.Conclusions: In conclusion, both the amitriptyline and pregabalin have significantly increased HRV and reduced the neuropathic pain intensity; but no correlation was observed between increased HRV and reduced neuropathic pain intensity.","PeriodicalId":13901,"journal":{"name":"International Journal of Basic & Clinical Pharmacology","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84814924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-23DOI: 10.18203/2319-2003.ijbcp20214887
B. Shaji, Jereena George, Aishwarya Shrestha, S. Stanly, N. Bose
Background: Stroke is considered as one of the important reasons of death and disability worldwide. A rational use of medications is needed to prevent the recurrence and the disease related complications.Methods: The current study is a prospective observational study. All stroke cases, with patients above the age of 25 and treated with antihypertensive agents were included in the study. A total of 189 patients were found suitable for inclusion in the study. Using a suitably designed data collection form, all pertinent data such as patient demographics, prescribed medicines, drug interactions and adverse drug reactions were collected from the patient’s case file, nurses’ charts, and medication charts. Prescription pattern of antihypertensive drugs were obtained. The causality of the ADR was assessed using the Naranjo causality assessment scale and reported in the institution where the study was conducted.Results: Majority of patients included in the study were in the age group of 61-70 years. The incidence of stroke in this study was more in males than in the females. Ischemic stroke (72%) was more prevalent when compared to Hemorrhagic stroke. Among the antihypertensive agents, calcium channel blockers (32%) were the most commonly prescribed class of drugs. In our audit, drug related problems were observed in 27% of the cases which included cases with improper dose (3 cases), contraindications (4 cases), major drug interactions (20 cases), and adverse drug reactions (17 cases). Most of the prescriptions were legible. Drug related problems had a great impact on the overall stroketherapy.Conclusions: The drug related problems are a relevant aspect to be considered when treating patients with stroke and it can arise irrespective of adherence to guidelines.
{"title":"Prescription audit of antihypertensive drugs used in stroke patients in a tertiary care teaching hospital","authors":"B. Shaji, Jereena George, Aishwarya Shrestha, S. Stanly, N. Bose","doi":"10.18203/2319-2003.ijbcp20214887","DOIUrl":"https://doi.org/10.18203/2319-2003.ijbcp20214887","url":null,"abstract":"Background: Stroke is considered as one of the important reasons of death and disability worldwide. A rational use of medications is needed to prevent the recurrence and the disease related complications.Methods: The current study is a prospective observational study. All stroke cases, with patients above the age of 25 and treated with antihypertensive agents were included in the study. A total of 189 patients were found suitable for inclusion in the study. Using a suitably designed data collection form, all pertinent data such as patient demographics, prescribed medicines, drug interactions and adverse drug reactions were collected from the patient’s case file, nurses’ charts, and medication charts. Prescription pattern of antihypertensive drugs were obtained. The causality of the ADR was assessed using the Naranjo causality assessment scale and reported in the institution where the study was conducted.Results: Majority of patients included in the study were in the age group of 61-70 years. The incidence of stroke in this study was more in males than in the females. Ischemic stroke (72%) was more prevalent when compared to Hemorrhagic stroke. Among the antihypertensive agents, calcium channel blockers (32%) were the most commonly prescribed class of drugs. In our audit, drug related problems were observed in 27% of the cases which included cases with improper dose (3 cases), contraindications (4 cases), major drug interactions (20 cases), and adverse drug reactions (17 cases). Most of the prescriptions were legible. Drug related problems had a great impact on the overall stroketherapy.Conclusions: The drug related problems are a relevant aspect to be considered when treating patients with stroke and it can arise irrespective of adherence to guidelines.","PeriodicalId":13901,"journal":{"name":"International Journal of Basic & Clinical Pharmacology","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77604806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：